Recombinant protein · Inhibitor of Hyaluronic acid · developed by Halozyme Therapeutics
Pegvorhyaluronidase alfa is a pegylated recombinant form of human hyaluronidase that degrades hyaluronic acid coating tumor cells and in the extracellular matrix. It is being studied in pancreatic, lung, and gastric or esophageal adenocarcinomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04134468 | Phase 2 | Pancreatic Ductal Adenocarcinoma | Withdrawn | HALO |
| NCT03281369 | Phase 1/2 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… | Terminated | BLRX |
| NCT01959139 | Phase 1/2 | Metastatic Pancreatic Adenocarcinoma | Completed | HALO |
| NCT02346370 | Phase 1 | Non-small Cell Lung Cancer | Terminated | HALO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Pancreatic AdenocarcinomaNon-small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the HALO page.
See HALO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HALO catalysts and pipeline →